KLP Kapitalforvaltning AS Acquires 26,300 Shares of Boston Scientific Corporation $BSX

KLP Kapitalforvaltning AS raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 4.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 614,056 shares of the medical equipment provider’s stock after buying an additional 26,300 shares during the period. KLP Kapitalforvaltning AS’s holdings in Boston Scientific were worth $65,956,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. 1248 Management LLC bought a new position in shares of Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific in the 1st quarter valued at about $27,000. Sound Income Strategies LLC raised its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific during the second quarter worth approximately $37,000. Finally, Activest Wealth Management boosted its holdings in shares of Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 373 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on BSX shares. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Canaccord Genuity Group boosted their target price on shares of Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. UBS Group raised their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Oppenheimer upgraded shares of Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Finally, Barclays increased their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $120.79.

Boston Scientific Trading Down 0.6%

Shares of Boston Scientific stock opened at $96.73 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a market capitalization of $143.33 billion, a price-to-earnings ratio of 57.58, a PEG ratio of 2.34 and a beta of 0.61. The firm’s 50-day moving average price is $102.75 and its two-hundred day moving average price is $102.04.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock valued at $17,972,457 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.